hrp0097p1-278 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2023

Exploration of O-link protein biomarkers in children born after IUGR and early impaired developmental changes in heart function

Änghagen Olov , Rudholm Feldreich Tobias , Ärnlöv Johan , Bang Peter

We recently assessed systolic heart function in children from IUGR and normal control pregnancies and reported early developmental impairment of left ventricular longitudinal strain – a sensitive echocardiographic measure – during the first 3 months of life in IUGR children. In accordance with previous studies, this suggest that the increased cardiovascular risk later in life imposed by IUGR/SGA may, at least to some extent, be primary and not entirely secondary to...

hrp0086p1-p111 | Bone & Mineral Metabolism P1 | ESPE2016

Impact of Conventional Medical Treatment on Bone Mineral Density and Bone Turnover in Adult XLH Patients: A 6 Year Cohort Study

Shanbhogue Vikram Vinod , Beck-Nielsen Signe Sparre

Background: X-linked hypophosphatemia (XLH) are rare, inheritable disorders caused by excessive renal phosphate wasting manifesting as rickets in children and osteomalacia in adults. While conventional medical treatment with oral phosphate and alfacalcidol is recommended in childhood, where it heals rickets and rescues some of the growth potential prior to fusion of the growth plates, it is controversial whether adults should continue therapy. There is little evidence for the ...

hrp0097p1-506 | Growth and Syndromes | ESPE2023

Characteristics, effectiveness and safety data for patients with growth failure treated with recombinant IGF-1 and achieving adult or near-adult height: results from the Increlex® Global Registry

Bang Peter , Ramón Krauel Marta , Maghnie Mohamad , Woelfle Joachim , Sert Caroline , Perrot Valérie , Pennestri Daniele , Polak Michel

Background: severe primary insulin-like growth factor-1 deficiency (SPIGFD) is a rare growth disorder. Recombinant human insulin-like growth factor (IGF-1) (rhIGF-1; Increlex® [mecasermin]) replacement therapy is EU and US-approved for treating growth failure due to SPIGFD. The long-term therapeutic objective of rhIGF-1 treatment in SPIGFD is to improve adult height (AH). Objective: to describe the characteristics, safety and effectiveness data ...

hrp0097p1-511 | Growth and Syndromes | ESPE2023

Pathway to assess severe primary IGF-1 deficiency diagnosis by using the IGF-1 generation test in a real-life setting: data from the Global Increlex® Registry

De Schepper Jean , Bossowski Artur , Argente Jesús , Sert Caroline , Perrot Valérie , Pennestri Daniele , Bang Peter

Background: severe primary insulin-like growth factor-1 deficiency (SPIGFD) is a rare growth disorder, for which insulin-like growth factor-1 (IGF-1) generation test (IGFGT) is debated as a complementary diagnostic analysis. Diagnostic workup for SPIGFD varies geographically and diagnosis is delayed by the rarity of the condition (<1/10,000). Evaluation of real-world practices of IGFGT could help facilitate diagnosis and test use. Objective: to describe rea...

hrp0084p2-330 | Fat | ESPE2015

Abdominal fat Distribution Measured by Magnetic Resonance Imaging in 197 Children Aged 10–15 Years – Correlation to Anthropometry and Dual X-Ray Absorptiometry

Tinggaard Jeanette , Hagen Casper P , Mouritsen Annette , Mieritz Mikkel G , Wohlfahrt-Veje Christine , Fallentin Eva , Larsen Rasmus , Christensen Anders N , Jensen Rikke B , Juul Anders , Main Katharina

Background: Obesity in childhood is defined by age- and sex-specific BMI cut-off values. However, BMI does not disclose the distribution of fat mass. Increased abdominal adipose tissue is associated with a higher risk of cardio-metabolic disease in adulthood. Thus, precise measurements of abdominal adipose tissue in children may enable early prevention of disease.Objective and hypotheses: To validate measurements of abdominal adipose tissue by anthropome...

hrp0094fc9.5 | Growth Hormone and IGFs | ESPE2021

Dynamic Changes in Growth and IGF-I During the First Year of Life; A Longitudinal Study of 233 healthy Danish Infants

Upners Emmie N. , Ljubicic Marie L , Busch Alexander S , Fischer Margit B , Almstrup Kristian , Petersen Jorgen H , Jensen Rikke B , Hagen Casper P , Juul Anders ,

Background: Growth during infancy is a continuation of the rapid fetal growth and its regulation is complex and multifactorial. It is well-established that insulin-like growth factor-I (IGF-I) and its regulators (e.g. IGF binding proteins (IGFBP-3) and pregnancy-associated plasma protein-A2 (PAPP-A2)) are important for prenatal and postnatal growth; however, their significance for growth during infancy is not fully explored.Aims: The aim...

hrp0089fc12.1 | Diabetes and Insulin 2 | ESPE2018

Continuous Glucose Monitoring Profiles in Healthy Non-Diabetic Children and Adolescents: A Multicenter Prospective Study

DuBose Stephanie , Li Zoey , Beck Roy , Tamborlane William

Since CGM-based outcomes that are increasingly being used in clinical pediatric diabetes research, this study was aimed at gathering normative sensor data in healthy, non-diabetic children using the recently approved DexCom G6 system. In this multicenter study, healthy, non-diabetic children and adolescents (age 7 to <18 years, BMI between 5th and 85th percentile, and HbA1c <5.7%) were included. Each participant wore a blinded DexCom G6 for approx. 10 days and kept a d...

hrp0086fc8.6 | Growth: Clinical | ESPE2016

Birth Characteristics Explain One Third of Expected Deaths in rhGH-treated Patients Diagnosed with IGHD, ISS & SGA

Albertsson-Wikland Kerstin , Martensson Anton , Savendahl Lars , Niklasson Aimon , Bang Peter , Dahlgren Jovanna , Gustafsson Jan , Kristrom Berit , Norgren Svante , Pehrsson Nils-Gunnar , Oden Anders

Background: That mortality is not increased in rhGH-treated patients when adjusting for birth characteristics was recently published (1). When applying a developed mortality model of the general population, the observed and expected deaths in rhGH-treated IGHD, ISS and SGA patients (n=3847) where 21 and 21.99, respectively. The model includes gender, age, calendar year, gestational age (GA), birth lengthSDS (BLSDS), birth weightSDS (BW...

hrp0089rfc11.3 | Bone, Growth Plate &amp; Mineral Metabolism 2 | ESPE2018

Increased Levels of Bone Formation and Resorption Markers in Patients with Hypophosphatemic Rickets

Hansen Stinus , Shanbhogue Vikram Vinod , Jorgensen Niklas Rye , Beck-Nielsen Signe Sparre

Background: X-linked hypophosphatemia (XLH) are rare inheritable disorders caused by excessive renal phosphate wasting manifesting as rickets in children and osteomalacia in adults. Osteoid accumulates due to the reduced mineralization rate. Based on previous histomorphometric bone biopsy studies it the impression that XLH is a low bone turnover disease. Very little is known about the level of bone markers in XLH and the effects of conventional medical treatment with oral phos...

hrp0086rfc6.5 | Syndromes: Mechanisms and Management | ESPE2016

Abnormal Videofluoroscopic Swallow Studies (VFSS) in Infants with Prader-Willi Syndrome Indicate a High Rate of Silent Aspiration

Salehi Parisa , Chen Maida , Beck Anita , McAfee Amber , Kim Soo-Jeong , Herzig Lisa , Leavitt Anne

Background: Prader-Willi Syndrome (PWS), due to loss of expression from genes within the PWS imprinted region at chromosome 15q11.2-13, is characterized by hypotonia and feeding intolerance in infancy with later development of hyperphagia and obesity. Growth hormone improves tone, body composition, and height and can be started in infancy. Morbidity and mortality in PWS include those secondary to hyperphagia and respiratory illness as well as a 17% reported incidence of sudden...